What this covers

This is a conversation between the host, John, and John Crowley, the biotech executive behind Amicus Therapeutics, and it is anchored in his work on Pompe disease. It begins with genetics: everyone carries recessive disease risk, and more than 7,000 known rare diseases, now over 10,000, are about 95 percent untreated. From there it moves into Pompe's biology, where glycogen builds up and destroys muscle, and into why a muscle-targeting Enzyme Replacement Therapy is harder than it looks. The first such therapy cut the children's enlarged hearts about threefold in 12 weeks, yet strength plateaued after a year. Amicus's own first small molecule made its first two adult patients weaker, forcing a Clinical Hold because its Half-Life in diseased muscle differed from healthy volunteers. Hung Do then left to start his own company, since Amicus could not afford a restart.

The wider industry picture covers a roughly decade-long development path, 90 percent clinic failure, and returns far more lopsided than in software. It also covers the overheating of biotech under zero interest rates and the correction that followed, and gene therapy hopes that outran the science. The Watershed Drug Effect is illustrated by AZT and HIV.

The more contested material is forward-looking. Crowley predicts blood tests that catch cancers early enough to make many of them chronic conditions, and modestly effective first Alzheimer's drugs. He also discusses GLP-1 drugs and the biology of obesity, AI in trial design, and pharma M&A as capital-efficient. He argues that regulatory science must keep pace with medical science, citing Peter Marks on expected gene editing approvals, and that US academic research is a national strategic asset.

Sharpest takeaway

Crowley argues that biotech's long, failure-prone path is survivable when leaders stay patient-focused, persistent, and well-capitalized, and that investors should diligence management character before technology.

  • Biotech outcomes are extremely skewed, and most core technologies fail, so the people running the company matter most
  • Companies die from running out of money rather than from trial failures, so capitalization is a survival requirement
  • Hope in biotech is a learned, disciplined practice tempered by reality, not an innate trait

The argument · threads5 threads · 83 claims
0.85

Early scientific and clinical hope often outruns reality, as Pompe, gene therapy, and early drugs show.

6 pointscentrality 5/5
  • Pharmacology measured in healthy volunteers and animals can mislead about how a drug behaves in the diseased patient population, so early data must be validated in the target patients.

    “It turns out that the half-life of the molecule in muscle in humans was different than it was in the animals and the healthy volunteers”

  • Making an enzyme replacement therapy for Pompe is deceptively hard because the enzyme must be safe, effective, and reach muscle, with targeting dependent on sugar carbohydrate decorations on the enzyme, a lock-and-key problem.

    “Megan and Patrick don't have that enzyme or don't make it correctly. And because of that, the glycogen builds up in muscles, and it devastates and destroys muscles.”

  • The first Pompe enzyme therapy reduced the enlarged left heart of the children by about 3x within 12 weeks, saving their lives, but muscle strength plateaued after about a year and the therapy was not a cure, requiring a next-generation effort.

    “The left side of their heart was 3x enlarged. Within 6 infusions, 12 weeks, their hearts had gone down to normal size”

  • Early Alzheimer's and neurodegeneration medicines may be modestly effective with hard side effects, just as the toxic early HIV drug AZT opened the path for later, better treatments.

    “The first medicine in HIV, AZT was a horribly toxic molecule, barely effective, but it opened up a watershed for biopharmaceutical companies”

  • Gene therapy was predicted to be about a year from clinical studies for Pompe roughly 25 years ago, yet the field still had not delivered, showing the gap between scientific hope and reality.

    “Oh, it's about a year from clinical studies. We're going to cure Pompe. That was more than almost 25 years ago now, and we're still not there.”

  • Gene therapy stalled for years after early successes because immune challenges, targeting, and manufacturing were hard, and in gene therapy the manufacturing process is itself the product.

    “The hopes, I think, started to exceed the reality. ... We needed to figure out how to make these gene therapies and manufacturing. The process is the product there.”

0.66

Failure is normal in biotech, so luck, humility, and learning from failed programs matter.

5 pointscentrality 4/5
  • The hardest judgment in biotech is knowing when persistence has become futility, and the team had to decide to stop the first Pompe molecule after months of trying alternatives before a new idea emerged.

    “And that's maybe the hardest thing in biotech is knowing you've got to be persistent. You've got to push, and we've done that many times. But when have you pushed far enough?”

  • Novozyme succeeded partly because the founders did not know how to build a biotech company and were driven by the need to save their children, so they lacked a template that might have constrained them.

    “probably because most of us, particularly me, didn't know what we were doing”

  • Crowley argues that biotech is a roller coaster in which failure is normal, and that the learnings from failed programs should be shared so others can pick up the research.

    “even when we fail in biotech, which we usually do, what are the learnings and how do we move on or how do we provide the seeds of learning for somebody else”

  • Crowley argues the early success of Novozyme involved luck, as there were many reasons it should have failed, so gratitude should coexist with humility about outcomes.

    “there's an element of luck. There's a thousand reasons we shouldn't have succeeded”

  • The Crowley family's Pompe experience shows that rare genetic disease affects everyone and that each new rare disease company can help reduce human suffering even when individual programs fail.

    “there was an opportunity to help put a little dent in the universe there and to alleviate hopefully some enormous family and human suffering”

0.57

Policy, regulation, and access must ensure promising medicines reach the patients who need them.

6 pointscentrality 3/5
  • Regulatory science is not advancing as fast as medical science, so regulators should adopt novel biostatistics, biomarkers, and creative trial designs for rare diseases while keeping the gold standard of safety and efficacy.

    “regulatory science is advancing as fast as medical science, and it's not”

  • As CEO of BIO, Crowley's priorities are policy, advocacy, and public education, with a new emphasis on access, meaning reimbursement, copays, and laws that block patients from medicines.

    “to focus on not only making newer and better medicines and technologies but to bringing them to everyone in need, that notion of access”

  • Roughly 70 percent of health care costs are attributed to lifestyle choices, so medicines that safely change those outcomes could have large societal benefit.

    “70% of all health care costs are due to lifestyle choices”

  • Companies should plan supply chains, import licenses, and regulatory pathways for compassionate use before pivotal trials finish, so a promising drug can reach anyone in need quickly.

    “we have to be prepared to provide it to anybody in need. And so, this notion of expanded access or compassionate use, we have to have that mindset and have to plan and prepare and have supplies, supply chains”

  • Drug development forms a virtuous circle with the patient at the center, flowing from university research through startups, venture capital, regulators, manufacturers, and diagnostics, with successful medicines funding the next cycle.

    “What it takes to make a medicine is this virtuous circle. And if you envision it, it is the patient in the middle.”

  • Biotech policy should ensure medicines reach people who need them, addressing copays, reimbursement, and laws that block access, as well as education about available treatments.

    “it's technical access maybe around copays and reimbursement and bad laws or policies that may prevent people from getting access to the medicines”

0.34

Generalist investors beat benchmarks through specialist diligence, while rates and hype distort valuations.

4 pointscentrality 2/5
  • When Amicus announced a major strategic repositioning, its stock rose only one cent because small companies get too much market noise, so investors do not reward announcements alone.

    “the stock went up $0.01 because nobody cares. We're a small company, too much noise”

  • Generalist investors do not need PhDs, but they need to know how to find and build specialist diligence teams and consult outside experts in academia, regulation, and disease to beat the benchmark modestly.

    “you don't need to be a scientist or a PhD if you're a generalist”

  • In biotech, beating the benchmark 60 percent of the time yields strong returns and a 70 percent hit rate makes an investor a rockstar, according to a Wall Street Journal article featuring Janus Henderson managers.

    “if you beat the benchmark, 60% of the time, you're going to do really, really well if you're 70%, you're a hero a rockstar in biotech”

  • Fast and high interest rates are unfriendly to long-dated biotech assets, because their value depends on distant future cash flows, and this pressured pre-revenue companies that depend on capital raises.

    “High interest rates are not the friends of long-dated assets, as you guys know better than almost anybody.”

0.34

Fit, character, and genuine passion matter more than credentials when choosing institutions and hiring people.

4 pointscentrality 2/5
  • Institutions can educate almost anyone, so the more important choice is where you fit and will thrive, based on the intangible character, values, and chemistry of the place.

    “countless institutions in America can educate you, but it's where are you going to fit?”

  • Long shared history and mutual adversity help couples frame difficulty, and during the early biotech years Aileen took on family responsibilities so John could build the company, which he calls love and sacrifice.

    “Aileen very courageously said, I'll do it. But I think for her taking that on to her shoulders”

  • Filling roles just because the company needs people during rapid growth leads to culture loss and retention problems, which forces leaders into HR firefighting and painful terminations.

    “We just put people in the seat because we needed people in the seat. And boy, when you're growing fast, you come to regret that very, very quickly.”

  • When building teams, treat the resume only as a threshold check for technical ability, then put it away and spend time with candidates, since resumes reveal little about passion or fit.

    “look at the resume once and do they cross the threshold for having on paper the technical abilities and then put it away, never look at it again and spend time with them.”